Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVES:To characterize plasma cytokine responses in melioidosis and analyse their association with mortality. METHODS:A prospective longitudinal study was conducted in two hospitals in Northeast Thailand to enroll 161 melioidosis patients, 13 uninfected healthy controls, and 11 uninfected diabetic controls. Blood was obtained from all individuals at enrollment (day 0) and at days 5, 12, and 28 from surviving melioidosis patients. IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-23, and TNF-α were assayed in plasma. The association of each cytokine and its dynamics with 28-day mortality was determined. RESULTS:Of melioidosis patients, 131/161 (81%) were bacteraemic, and 68/161 (42%) died. On enrollment median levels of IFN-γ, IL-6, IL-8, IL-10, IL-23, and TNF-α were higher in melioidosis patients compared with uninfected healthy controls and all but IFN-γ were positively associated with 28-day mortality. IL-8 provided the best discrimination of mortality (AUROCC 0.78, 95% CI 0.71-0.85). Over time, non-survivors had increasing IL-6, IL-8, and IL-17A levels, in contrast to survivors. In joint modeling, temporal trajectories of IFN-γ, IL-6, IL-8, IL-10, and TNF-α predicted survival. CONCLUSIONS:In a severely ill cohort of melioidosis patients, specific pro- and anti-inflammatory and Th17 cytokines were associated with survival from melioidosis, at enrollment and over time. Persistent inflammation preceded death. These findings support further evaluation of these mediators as prognostic biomarkers and to guide targeted immunotherapeutic development for severe melioidosis.

Original publication

DOI

10.1016/j.cmi.2019.10.032

Type

Journal article

Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Publication Date

06/11/2019

Addresses

Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.